Abstract
The Met tyrosine kinase receptor is a widely expressed molecule, which mediates pleiotropic cellular responses following activation by its ligand, hepatocyte growth factor/scatter factor (HGF/SF). Previously, one of the authors identified an alternatively spliced form of Met (Met-SM) that lacked a single exon of a 47-amino-acid segment in the juxtamembrane domain. Here we report that Met-SM is a potent transforming gene in NIH3T3 mouse fibroblast cells. Met-SM-transfected NIH3T3 cells show stronger foci-forming activity than wild type-Met-transfected ones. In addition, Met-SM-transfected NIH3T3 cells form colonies in soft agar and are tumorigenic in athymic nu/nu mice. Furthermore, HGF/SF significantly increases the focus-forming activity of Met-SM comparing to wild type Met. The amount of protein and of tyrosine kinase activity of Met-SM accumulates to a high level following HGF/SF treatment. The accumulation of Met-SM correlated well with its delayed ubiquitination and increased stability. These results are consistent with the important role of the juxtamembrane domain in protein stability of Met receptor and suggest that the alternatively-spliced form may contribute to the development and progression of human cancer.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Lee, JH., Gao, C., Lee, C. et al. An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med 38, 565–573 (2006). https://doi.org/10.1038/emm.2006.66
Published:
Issue Date:
DOI: https://doi.org/10.1038/emm.2006.66
Keywords
This article is cited by
-
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling
British Journal of Cancer (2024)
-
The role of RNA alternative splicing in regulating cancer metabolism
Human Genetics (2017)
-
89Zr-Onartuzumab PET imaging of c-MET receptor dynamics
European Journal of Nuclear Medicine and Molecular Imaging (2017)
-
Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain
Cell Communication and Signaling (2014)